KG

Kuriyan Goerge

Active Director Director DIN 11777093
DIN 11777093 First appointment Jun 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Kuriyan Goerge

Kuriyan Goerge is a Director at Adradices Biotech Private Limited (since 2026).

DIN 11777093
Primary Designation Director
First Appointment 18 Jun 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Adradices Biotech Private Limited U72200KL2026PTC103967
Director18 Jun 20262026Active

Board colleagues of Kuriyan Goerge

NameDINCompanyDesignation
Sain Jose11777095Adradices Biotech Private LimitedDirector
Sebastian Baisel10258076Adradices Biotech Private LimitedDirector
Shiney George11777094Adradices Biotech Private LimitedDirector/Designated Partner

Directorship timeline

Open interactive timeline →
Adradices Biotech Private Limited
Premium access

Shareholding and investment profile for Kuriyan Goerge

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kuriyan Goerge

Kuriyan Goerge currently holds 1 directorship: Adradices Biotech Private Limited (Director, since 18 Jun 2026).

Kuriyan Goerge was first appointed on 18 Jun 2026 as Director at Adradices Biotech Private Limited.

The current boards of Kuriyan Goerge's companies include Sain Jose (Adradices Biotech Private Limited), Sebastian Baisel (Adradices Biotech Private Limited), Shiney George (Adradices Biotech Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available